Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000
Debt
Debt-to-Equity Ratio-3.20
Current Ratio4.03
Quick Ratio4.03
Price-To-Earnings
Trailing P/E Ratio-2.22
Forward P/E Ratio-2.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.18 million
Price / Sales17.01
Cash FlowN/A
Price / CashN/A
Book Value($0.31) per share
Price / Book-4.48
Profitability
EPS (Most Recent Fiscal Year)($0.63)
Net Income$-183,760,000.00
Net Margins-529.93%
Return on EquityN/A
Return on Assets-58.74%
Miscellaneous
Employees347
Outstanding Shares381,670,000
Market Cap$519.08
Novavax (NASDAQ:NVAX) Frequently Asked Questions
What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
How were Novavax's earnings last quarter?
Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $9.70 million during the quarter, compared to analyst estimates of $9.33 million. The company's revenue for the quarter was up 70.2% compared to the same quarter last year. During the same period last year, the business posted ($0.16) earnings per share. View Novavax's Earnings History.
What price target have analysts set for NVAX?
8 brokers have issued 12-month target prices for Novavax's stock. Their forecasts range from $1.35 to $10.00. On average, they anticipate Novavax's share price to reach $3.5125 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price. View Analyst Ratings for Novavax.
What is the consensus analysts' recommendation for Novavax?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Novavax stock?
Here are some recent quotes from research analysts about Novavax stock:
- 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (5/15/2018)
- 2. Cantor Fitzgerald analysts commented, "NanoFlu seasonal flu vaccine could be just what the Dr. ordered. The mismatch of commercially available (egg-production-based) seasonal flu vaccines in the current season underscores the theoretical utility of NVAX’s vaccine production technology. Avoiding influenza virus propagation in eggs could reduce the need for egg adaptation and possible generation of virus particles that do not faithfully resemble the wild type viruses recommended by health organizations for inclusion in flu vaccines. Particularly when prevailing strains are highly pathogenic, e.g., H3N2, having a better matched flu vaccine would seem to be desirable, in our view." (3/15/2018)
Are investors shorting Novavax?
Novavax saw a increase in short interest in June. As of June 29th, there was short interest totalling 52,477,400 shares, an increase of 4.6% from the June 15th total of 50,163,541 shares. Based on an average trading volume of 5,702,535 shares, the days-to-cover ratio is currently 9.2 days. Approximately 13.9% of the company's shares are sold short. View Novavax's Current Options Chain.
Who are some of Novavax's key competitors?
Some companies that are related to Novavax include Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), Solid Biosciences (SLDB), Sangamo Therapeutics (SGMO), Acorda Therapeutics (ACOR), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Cellectis (CLLS), DBV Technologies (DBVT), Adaptimmune Therapeutics (ADAP), BAVARIAN NORDIC/S (BVNRY), Coherus Biosciences (CHRS), Autolus Therapeutics (AUTL) and Heska (HSKA).
Who are Novavax's key executives?
Novavax's management team includes the folowing people:
- Mr. Stanley Charles Erck, Pres, CEO & Director (Age 70)
- Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 58)
- Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 52)
- Dr. Gregory M. Glenn, Pres of R&D (Age 64)
- Ms. Jill Hoyt, VP of HR & Admin.
Has Novavax been receiving favorable news coverage?
Media coverage about NVAX stock has trended somewhat negative recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Novavax earned a media sentiment score of -0.08 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 42.56 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Novavax?
Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novavax's stock price today?
One share of NVAX stock can currently be purchased for approximately $1.39.
How big of a company is Novavax?
Novavax has a market capitalization of $519.08 million and generates $31.18 million in revenue each year. The biopharmaceutical company earns $-183,760,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Novavax employs 347 workers across the globe.
How can I contact Novavax?
Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]
MarketBeat Community Rating for Novavax (NASDAQ NVAX)
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
